Comparison · NCT00129766-f5c73caf
Palivizumab vs Motavizumab: The Incidence of RSV-specific Medically-attended Outpatient Lower Respiratory Illnesses (LRIs) Between Treatment Groups
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Palivizumab vs Motavizumab: The Incidence of RSV-specific Medically-attended Outpatient Lower Respiratory Illnesses (LRIs) Between Treatment Groups. Trial comparisons, record NCT00129766-f5c73caf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00129766-f5c73caf
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0389 | 0.0293 | 0.0515 | wilson | |
| Risk in group 2 | 0.0196 | 0.0132 | 0.0289 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0193 | 0.0059 | 0.0334 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.99 | 1.22 | 3.24 | log | |
| Odds ratio, group 1 over group 2 | 2.03 | 1.23 | 3.34 | log | |
| Number needed to treat, for one more participant with the outcome on Palivizumab than on Motavizumab | 51.7 | 29.9 | 170 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Palivizumab | Palivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses | 46 | 1,183 | OG000 |
| Group 2 | Motavizumab | Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses | 24 | 1,227 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- The Incidence of RSV-specific Medically-attended Outpatient Lower Respiratory Illnesses (LRIs) Between Treatment Groups
- Description
- The RSV-specific LRI was defined as an outpatient medically-attended LRI associated with a positive RSV test and was not inclusive of events that required hospitalization.
- Time frame
- Days 0 - 150
- Population
- Subjects were from a pre-specified subsets of sites participating in the nasal secretion sample collection for this endpoint.
Source ClinicalTrials.gov
Trial
- Title
- Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
- NCT number
- NCT00129766
- Phases
- PHASE3
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- motavizumab (MEDI-524), palivizumab
- Lead sponsor
- MedImmune LLC
- Results first posted
- 2013-08-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00129766?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00129766-f5c73caf